4,000-Patient study aims to unlock mysteries of rare liver disease

NCT ID NCT07149675

Recruiting now Knowledge-focused Sponsor: Beijing Friendship Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study will follow 4,000 people with primary biliary cholangitis (PBC), a chronic autoimmune liver disease, across multiple hospitals in China. Researchers will track survival, need for liver transplant, and common symptoms like fatigue and itching. The goal is to better understand how the disease progresses and how well current treatments work in a real-world setting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this study could help doctors better predict outcomes and tailor treatments for people with primary biliary cholangitis in China.
What could go wrong: This is an observational study, not a treatment trial. It will not test new drugs or directly improve health. Results may not apply outside China.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LONG TERM OUTCOMES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

primary biliary cholangitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LONG TERM OUTCOMES MULTICENTER PROSPECTIVE STUDY PRIMARY BILIARY CHOLANGITIS (PBC) PROGNOSIS

Contacts and locations

Locations

Liver Research Center, Beijing Friendship Hospital, Capital Medical University
RECRUITING

Beijing, Select A State Or Province, 100069, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.